Abstract
Kennedy’ s disease (KD) or spinobulbar muscular atrophy is a hereditary X-linked, progressive neurodegenerative condition caused by an expansion of the CAG triplet repeat in the first exon of the androgen receptor gene. The phenotype in its full form is only expressed in males and presents as weakness and wasting of the upper and lower limbs and bulbarmuscles associated with absent reflexes. Sensory disturbances are present. Various endocrine abnormalities including decreased fertility and gynecomastia are common and amongst the first features of KD. Animal models of KD have demonstrated improvement on withdrawal of testosterone, indicating that this agonist of the androgen receptor is required for the toxic effect. Potential therapies based on testosterone withdrawal in humans have shown some promise, but efficacy remains to be proven. Potential clinical factors, pathogenesis and future approaches to therapy are reviewed in this chapter.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
MacLean HE, Warne GL, Zajac JD. Spinal and bulbar muscular atrophy: androgen receptor dysfunction caused by a trinucleotide repeat expansion. J Neurol Sci 1996; 135(2):149–157.
Lund A, Udd B, Juvonen V et al. Multiple founder effects in spinal and bulbar muscular atrophy (SBMA, Kennedy disease) around the world. Eur J Hum Genet 2001; 9(6):431–436.
Chahin N, Klein C, Mandrekar J et al. Natural history of spinal-bulbar muscular atrophy. Neurology 2008; 70(21):1967–1971.
MacLean HE, Choi WT, Rekaris G et al. Abnormal androgen receptor binding affinity in subjects with Kennedy’s disease (spinal and bulbar muscular atrophy). J Clin Endocrinol Metab 1995; 80(2):508–516.
Atsuta N, Watanabe H, Ito M et al. Natural history of spinal and bulbar muscular atrophy (SBMA): a study of 223 Japanese patients. Brain 2006; 129(Pt 6): 1446–1455.
Hanajima R, Terao Y, Nakatani-Enomoto S et al. Postural tremor in X-linked spinal and bulbar muscular atrophy. Mov Disord 2009; 24(14):2063–2069.
Sperfeld AD, Hanemann CO, Ludolph AC et al. Laryngospasm: an underdiagnosed symptom of X-linked spinobulbar muscular atrophy. Neurology 2005; 64(4):753–754.
Dejager S, Bry-Gauillard H, Bruckert E et al. A comprehensive endocrine description of Kennedy’s disease revealing androgen insensitivity linked to CAG repeat length. J Clin Endocrinol Metab 2002; 87(8):3893–3901.
Zajac JD, MacLean HE. Kennedy’s disease: clinical aspects. In: Wells RD, Warren ST, Sarmiento M, eds. Genetic Instabilities and Hereditary Neurological Diseases. San Diego: Academic Press; 1998:87–100.
Kennedy WR, Alter M, Sung JH. Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait. Neurology 1968; 18(7):671–680.
Lee JH, Shin JH, Park KP et al. Phenotypic variability in Kennedy’s disease: implication of the early diagnostic features. Acta Neurol Scand 2005; 112(1):57–63.
Kassubek J, Juengling FD, Sperfeld AD. Widespread white matter changes in Kennedy disease: a voxel based morphometry study. J Neurol Neurosurg Psychiatry 2007; 78(11): 1209–1212.
Soragna D, Messa C, Mochi M et al. Dopaminergic pathways involvement in Kennedy’s disease: neurophysiological and. Journal of Neurology 2001; 248(8):710–712.
Shaw PJ, Thagesen H, Tomkins J et al. Kennedy’s disease: unusual molecular pathologic and clinical features. Neurology 1998; 51(1):252–255.
Ishihara H, Kanda F, Nishio H et al. Clinical features and skewed X-chromosome inactivation in female carriers of X-linked recessive spinal and bulbar muscular atrophy. J Neurol 2001; 248(10):856–860.
Schmidt BJ, Greenberg CR, Allingham-Hawkins DJ et al. Expression of X-linked bulbospinal muscular atrophy (Kennedy disease) in two homozygous women. Neurology 2002; 59(5):770–772.
Johansen JA, Yu Z, Mo K et al. Recovery of function in a myogenic mouse model of spinal bulbar muscular atrophy. Neurobiol Dis 2009; 34(1):113–120.
Ferrante MA, Wilbourn AJ. The characteristic electrodiagnostic features of Kennedy’s disease. Muscle Nerve 1997; 20(3):323–329.
Suzuki K, Katsuno M, Banno H et al. CAG repeat size correlates to electrophysiological motor and sensory phenotypes in SBMA. Brain 2008; 131(Pt l):229–239.
Sobue G, Hashizume Y, Mukai E et al. X-linked recessive bulbospinal neuronopathy. A clinicopathological study. Brain 1989; 112(Pt l):209–232.
Harding AE, Thomas PK, Baraitser M et al. X-linked recessive bulbospinal neuronopathy: a report of ten cases. J Neurol Neurosurg Psychiatry 1982; 45(11): 1012–1019.
Li M, Sobue G, Doyu M et al. Primary sensory neurons in X-linked recessive bulbospinal neuropathy: histopathology and androgen receptor gene expression. Muscle Nerve 1995; 18(3):301–308.
Soraru G, D’Ascenzo C, Polo A et al. Spinal and bulbar muscular atrophy: skeletal muscle pathology in male patients and heterozygous females. Journal of the Neurological Sciences 2008; 264(1–2): 100–105.
Soukup GR, Sperfeld AD, Uttner I et al. Frontotemporal cognitive function in X’linked spinal and bulbar muscular atrophy (SBMA): a controlled neuropsychological study of 20 patients. Journal of Neurology 2009;256(11):1869–1875.
Logroscino G, Traynor BJ, Hardiman O et al. Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. J Neurol Neurosurg Psychiatry 2008; 79(1):6–11.
McDermott CJ, Shaw PJ. Diagnosis and management of motor neurone disease. BMJ 2008; 336(7645): 658–662.
Corcia P, Meininger V. Management of amyotrophic lateral sclerosis. Drugs 2008; 68(8):1037–1048.
van der Graaff MM, de Jong JM, Baas F et al. Upper motor neuron and extra-motor neuron involvement in amyotrophic lateral sclerosis: aclinical and brain imagingreview. Neuromuscul Disord 2009; 19(1):53–58.
Pugdahl K, Fuglsang-Frederiksen A, de Carvalho M et al. Generalised sensory system abnormalities in amyotrophic lateral sclerosis: a European multicentre study. J Neurol Neurosurg Psychiatry 2007; 78(7):746–749.
Amoiridis G, Tsimoulis D, Ameridou I. Clinical, electrophysiologic and pathologic evidence for sensory abnormalities in ALS. Neurology 2008; 71(10):779.
Suzuki K, Katsuno M, Banno H et al. The profile of motor unit number estimation (MUNE) in spinal and bulbar muscular atrophy. J Neurol Neurosurg Psychiatry 2010; 81(5):567–571.
La Spada AR, Wilson EM, Lubahn DB et al. Androgen receptor gene mutations in X’linked spinal and bulbar muscular atrophy. Nature 1991; 352(6330):77–79.
Greenland KJ, Zajac JD. Kennedy’s disease: pathogenesis and clinical approaches. Intern Med J 2004; 34(5):279–286.
Adachi H, Katsuno M, Minamiyama M et al. Widespread nuclear and cytoplasmic accumulation of mutant androgen receptor in SBMA patients. Brain 2005; 128(Pt 3):659–670.
Li M, Miwa S, Kobayashi Y et al. Nuclear inclusions of the androgen receptor protein in spinal and bulbar muscular atrophy. Annals of Neurology 1998; 44(2):249–254.
Grossmann M, Thomas MC, Panagiotopoulos S et al. Low testosterone levels are common and associated with insulin resistance in men with diabetes. J Clin Endocrinol Metab 2008; 93(5): 1834–1840.
MacLean HE, Ball EM, Rekaris G et al. Novel androgen receptor gene mutations in Australian patients with complete androgen insensitivity syndrome. Hum Mutat 2004; 23(3):287.
Yeh S, Tsai MY, Xu Q et al. Generation and characterization of androgen receptor knockout (ARKO) mice: an in vivo model for the study of androgen functions in selective tissues. Proc Natl Acad Sci USA 2002;99(21):13498–13503.
Notini AJ, Davey RA, McManus JF et al. Genomic actions of the androgen receptor are required for normal male sexual differentiation in a mouse model. J Mol Endocrinol 2005; 35(3):547–555.
Mariotti C, Castellotti B, Pareyson D et al. Phenotypic manifestations associated with CAG-repeat expansion in the androgen receptor gene in male patients and heterozygous females: a clinical and molecular study of 30 families. Neuromuscul Disord 2000; 10(6):391–397.
Thomas PS Jr., Fraley GS, Damian V et al. Loss of endogenous androgen receptor protein accelerates motor neuron degeneration and accentuates androgen insensitivity in a mouse model of X’linked spinal and bulbar muscular atrophy. Hum Mol Genet 2006; 15(14):2225–2238.
Cary GA, La Spada AR. Androgen receptor function in motor neuron survival and degeneration. Phys Med Rehabil Clin N Am 2008; 19(3):479–494, viii.
Poletti A, Negri-Cesi P, Martini L. Reflections on the diseases linked to mutations of the androgen receptor. Endocrine 2005; 28(3):243–262.
Walsh R, Storey E, Stefani D et al. The roles of proteolysis and nuclear localisation in the toxicity of the polyglutamine diseases. A review. Neurotox Res 2005; 7(1–2):43–57.
McCampbell A, Taylor JP, Taye AA et al. CREB-binding protein sequestration by expanded polyglutamine. Hum Mol Genet 2000; 9(14):2197–2202.
Minamiyama M, Katsuno M, Adachi H et al. Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet 2004; 13(11): 1183–1192.
Walcott JL, Merry DE. Ligand promotes intranuclear inclusions in a novel cell model of spinal and bulbar muscular atrophy. J Biol Chem 2002; 277(52):50855–50859.
Chan HY, Warrick JM, Andriola I et al. Genetic modulation of polyglutamine toxicity by protein conjugation pathways in Drosophila. Human Molecular Genetics 2002; 11(23):2895–2904.
Morfini G, Pigino G, Szebenyi G et al. JNK mediates pathogenic effects of polyglutamine-expanded androgen receptor on fast axonal transport. Nat Neurosci 2006; 9(7):907–916.
Katsuno M, Adachi H, Minamiyama M et al. Disrupted transforming growth factor-beta signaling in spinal and bulbar muscular atrophy. Journal of Neuroscience 2010; 30(16):5702–5712.
Ellerby LM, Hackam AS, Propp SS et al. Kennedy’s disease: caspase cleavage of the androgen receptor is a crucial event in cytotoxicity. J Neurochem 1999; 72(1):185–195.
Adachi H, Katsuno M, Minamiyama M et al. Heat shock protein 70 chaperone overexpression ameliorates phenotypes of the spinal and bulbarmuscularatrophytransgenic mouse modelbyreducingnuclear-localized mutant androgen receptor protein. J Neurosci 2003; 23(6):2203–2211.
Paulson HL, Perez MK, Trottier Y et al. Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron 1997; 19(2):333–344.
Li M, Nakagomi Y, Kobayashi Y et al. Nonneural nuclear inclusions of androgen receptor protein in spinal and bulbar muscular atrophy. Am J Pathol 1998; 153(3):695–701.
Beitel LK, Scanlon T, Gottlieb B et al. Progress in spinobulbar muscular atrophy research: insights into neuronal dysfunction caused by the polyglutamine-expanded androgen receptor. Neurotox Res 2005; 7(3):219–230.
Chevalier-Larsen ES, O’Brien CJ, Wang H et al. Castration restores function and neurofilament alterations of aged symptomatic males in atransgenic mouse model of spinal and bulbar muscular atrophy. J Neurosci 2004; 24(20):4778–4786.
Katsuno M, Banno H, Suzuki K et al. Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9(9):875–884.
Matsumoto A, Micevych PE, Arnold AP. Androgen regulates synaptic input to motoneurons of the adult rat spinal cord. J Neurosci 1988; 8(11):4168–4176.
Goldstein LA, Sengelaub DR. Timing and duration of dihydrotestosterone treatment affect the development of motoneuron number and morphology in a sexually dimorphic rat spinal nucleus. J Comp Neurol 1992; 326(1):147–157.
Watson NV, Freeman LM, Breedlove SM. Neuronal size in the spinal nucleus of the bulbocavernosus: direct modulation by androgen in rats with mosaic androgen insensitivity. J Neurosci 2001; 21(3): 1062–1066.
Schroder HD, Reske-Nielsen E. Preservation of the nucleus X-pelvic floor motosystem in amyotrophic lateral sclerosis. Clin Neuropathol 1984; 3(5):210–216.
Katsuno M, Adachi H, Minamiyama M et al. Reversible disruption of dynactin 1-mediated retrograde axonal transport in polyglutamine-induced motor neuron degeneration. Journal of Neuroscience 2006; 26(47):12106–12117.
Takeyama K, Ito S, Yamamoto A et al. Androgen-dependent neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila. Neuron 2002; 35(5):855–864.
McManamny P, Chy HS, Finkelstein DI et al. A mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet 2002; 11(18):2103–2111.
Abel A, Walcott J, Woods J et al. Expression of expanded repeat androgen receptor produces neurologic disease in transgenic mice. Hum Mol Genet 2001; 10(2):107–116.
Kinirons P, Rouleau GA. Administration of testosterone results in reversible deterioration in Kennedy’s disease. J Neurol Neurosurg Psychiatry 2008; 79(1):106–107.
Goldenberg JN, Bradley WG. Testosterone therapy and the pathogenesis of Kennedy’s disease (X’linked bulbospinal muscular atrophy). Journal of the Neurological Sciences 1996; 135(2): 158–161.
Katsuno M, Adachi H, Kume A et al. Testosterone reduction prevents phenotypic expression in atransgenic mouse model of spinal and bulbar muscular atrophy. Neuron 2002; 35(5):843–854.
Katsuno M, Adachi H, Doyu M et al. Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat Med 2003; 9(6):768–773.
Yang Z, Chang YJ, Yu IC et al. ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor. Nat Med 2007; 13(3):348–353.
Tokui K, Adachi H, Waza M et al. 17-DMAGameliorates polyglutamine-mediated motor neuron degeneration through well-preserved proteasome function in an SBMA model mouse. Human Molecular Genetics 2009; 18(5):898–910.
Adachi H, Waza M, Tokui K et al. CHIP overexpression reduces mutant androgen receptor protein and ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model. Journal of Neuroscience 2007; 27(19):5115–5126.
Palazzolol, Stack C, Kong L et al. Overexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy. Neuron 2009; 63(3):316–328.
Banno H, Katsuno M, Suzuki K et al. Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. Annals of Neurology 2009; 65(2):140–150.
Shahani S, Braga-Basaria M, Basaria S. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. J Clin Endocrinol Metab 2008; 93(6):2042–2049.
Greenspan SL. Approach to the prostate cancer patient with bone disease. J Clin Endocrinol Metab 2008; 93(1):2–7.
Grossmann M. Bone and metabolic health in patients with nonmetastatic prostate cancer receiving androgen deprivation therapy — management guidelines. Med J Aust. In Press.
Waza M, Adachi H, Katsuno M et al. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat Med 2005; 11(10):1088–1095.
Banerji U, O’Donnell A, Scurr M et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demetho xygeldanamycin in patients with advancedmalignancies. J Clin Oncol 2005; 23(18):4152–4161.
Piccioni F, Roman BR, Fischbeck KH et al. A screen for drugs that protect against the cytotoxicity of polyglutamine-expanded androgen receptor. Hum Mol Genet 2004; 13(4):437–446.
Caplen NJ, Taylor JP, Statham VS et al. Rescue of polyglutamine-mediated cytotoxicity by double-stranded RNA-mediated RNA interference. Hum Mol Genet 2002; 11(2):175–184.
Takeuchi Y, Katsuno M, Banno H et al. Walking capacity evaluated by the 6-minute walk test in spinal and bulbar muscular atrophy. Muscle Nerve 2008; 38(2):964–971.
Banno H, Adachi H, Katsuno M et al. Mutant androgen receptor accumulation in spinal and bulbar muscular atrophy scrotal skin: a pathogenic marker. Annals of Neurology 2006; 59(3):520–526.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Landes Bioscience and Springer Science+Business Media
About this chapter
Cite this chapter
Zajac, J.D., Fui, M.N.T. (2012). Kennedy’s Disease. In: Hannan, A.J. (eds) Tandem Repeat Polymorphisms. Advances in Experimental Medicine and Biology. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5434-2_10
Download citation
DOI: https://doi.org/10.1007/978-1-4614-5434-2_10
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-5433-5
Online ISBN: 978-1-4614-5434-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)